Johnson & Johnson Logo

Email this page: News Release

FDA Issues Complete Response Letter for XARELTO® (rivaroxaban) for the Reduction of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

® (rivaroxaban) for the Reduction of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome" />
 

Separate multiple addresses with commas. Maximum 200 characters.
 
 


These email addresses will be used to email the page on your behalf and will not be used by Johnson & Johnson for any marketing purposes.

Send:       


 
This helps Johnson & Johnson prevent automated submissions.